FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805565362> ?p ?o ?g. }

• W2805565362 abstract "A phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was designed to collect FDA-required safety/toxicity data to support FDA registration of ch14.18.Newly diagnosed high-risk NB patients who achieved at least a partial response to induction therapy and received myeloablative consolidation with stem cell rescue were enrolled to receive six courses of isotretinoin with five concomitant cycles of ch14.18 combined with GM-CSF or IL2. Ch14.18 infusion time was 10-20 h per dose. Blood was collected for cytokine analysis and its association with toxicities and outcome.Of 105 patients enrolled, five patients developed protocol-defined unacceptable toxicities. The most common grade ≥ 3 non-hematologic toxicities of immunotherapy for cycles 1-5, respectively, were neuropathic pain (41, 28, 22, 31, 24%), hypotension (10, 17, 4, 14, 8%), allergic reactions (ARs) (3, 10, 5, 7, 2%), capillary leak syndrome (1, 4, 0, 2, 0%), and fever (21, 59, 6, 32, 5%). The 3-year event-free survival and overall survival were 67.6 ± 4.8% and 79.1 ± 4.2%, respectively. AR during course 1 was associated with elevated serum levels of IL-1Ra and IFNγ, while severe hypotension during this course was associated with low IL5 and nitrate. Higher pretreatment CXCL9 level was associated with poorer event-free survival (EFS).This study has confirmed the significant, but manageable treatment-related toxicities of this immunotherapy and identified possible cytokine biomarkers associated with select toxicities and outcome. EFS and OS appear similar to that previously reported on ANBL0032." @default.
• W2805565362 created "2018-06-13" @default.
• W2805565362 creator A5000459362 @default.
• W2805565362 creator A5003639088 @default.
• W2805565362 creator A5005797590 @default.
• W2805565362 creator A5011569932 @default.
• W2805565362 creator A5013467643 @default.
• W2805565362 creator A5014556553 @default.
• W2805565362 creator A5017501517 @default.
• W2805565362 creator A5018957253 @default.
• W2805565362 creator A5026627434 @default.
• W2805565362 creator A5031797401 @default.
• W2805565362 creator A5041707000 @default.
• W2805565362 creator A5055664953 @default.
• W2805565362 creator A5058354009 @default.
• W2805565362 creator A5067145358 @default.
• W2805565362 creator A5072839298 @default.
• W2805565362 creator A5077521470 @default.
• W2805565362 creator A5079060579 @default.
• W2805565362 date "2018-06-18" @default.
• W2805565362 modified "2023-09-30" @default.
• W2805565362 title "A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931" @default.
• W2805565362 cites W1587504796 @default.
• W2805565362 cites W1969752769 @default.
• W2805565362 cites W1970865970 @default.
• W2805565362 cites W1989121912 @default.
• W2805565362 cites W2012046793 @default.
• W2805565362 cites W2021963251 @default.
• W2805565362 cites W2027621777 @default.
• W2805565362 cites W2038252730 @default.
• W2805565362 cites W2054435322 @default.
• W2805565362 cites W2054911916 @default.
• W2805565362 cites W2061366514 @default.
• W2805565362 cites W2061770965 @default.
• W2805565362 cites W2088889797 @default.
• W2805565362 cites W2090922241 @default.
• W2805565362 cites W2096398040 @default.
• W2805565362 cites W2110134768 @default.
• W2805565362 cites W2114784836 @default.
• W2805565362 cites W2114993851 @default.
• W2805565362 cites W2121146521 @default.
• W2805565362 cites W2128870897 @default.
• W2805565362 cites W2130465135 @default.
• W2805565362 cites W2155614959 @default.
• W2805565362 cites W2263972934 @default.
• W2805565362 cites W2293124958 @default.
• W2805565362 cites W2417109520 @default.
• W2805565362 cites W2767789735 @default.
• W2805565362 cites W4240339669 @default.
• W2805565362 cites W4293241248 @default.
• W2805565362 doi "https://doi.org/10.3389/fimmu.2018.01355" @default.
• W2805565362 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6055015" @default.
• W2805565362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30046297" @default.
• W2805565362 hasPublicationYear "2018" @default.
• W2805565362 type Work @default.
• W2805565362 sameAs 2805565362 @default.
• W2805565362 citedByCount "61" @default.
• W2805565362 countsByYear W28055653622018 @default.
• W2805565362 countsByYear W28055653622019 @default.
• W2805565362 countsByYear W28055653622020 @default.
• W2805565362 countsByYear W28055653622021 @default.
• W2805565362 countsByYear W28055653622022 @default.
• W2805565362 countsByYear W28055653622023 @default.
• W2805565362 crossrefType "journal-article" @default.
• W2805565362 hasAuthorship W2805565362A5000459362 @default.
• W2805565362 hasAuthorship W2805565362A5003639088 @default.
• W2805565362 hasAuthorship W2805565362A5005797590 @default.
• W2805565362 hasAuthorship W2805565362A5011569932 @default.
• W2805565362 hasAuthorship W2805565362A5013467643 @default.
• W2805565362 hasAuthorship W2805565362A5014556553 @default.
• W2805565362 hasAuthorship W2805565362A5017501517 @default.
• W2805565362 hasAuthorship W2805565362A5018957253 @default.
• W2805565362 hasAuthorship W2805565362A5026627434 @default.
• W2805565362 hasAuthorship W2805565362A5031797401 @default.
• W2805565362 hasAuthorship W2805565362A5041707000 @default.
• W2805565362 hasAuthorship W2805565362A5055664953 @default.
• W2805565362 hasAuthorship W2805565362A5058354009 @default.
• W2805565362 hasAuthorship W2805565362A5067145358 @default.
• W2805565362 hasAuthorship W2805565362A5072839298 @default.
• W2805565362 hasAuthorship W2805565362A5077521470 @default.
• W2805565362 hasAuthorship W2805565362A5079060579 @default.
• W2805565362 hasBestOaLocation W28055653621 @default.
• W2805565362 hasConcept C121608353 @default.
• W2805565362 hasConcept C126322002 @default.
• W2805565362 hasConcept C141071460 @default.
• W2805565362 hasConcept C143998085 @default.
• W2805565362 hasConcept C16005928 @default.
• W2805565362 hasConcept C2776285725 @default.
• W2805565362 hasConcept C2777673923 @default.
• W2805565362 hasConcept C2777701055 @default.
• W2805565362 hasConcept C2779384505 @default.
• W2805565362 hasConcept C71924100 @default.
• W2805565362 hasConcept C90924648 @default.
• W2805565362 hasConceptScore W2805565362C121608353 @default.
• W2805565362 hasConceptScore W2805565362C126322002 @default.
• W2805565362 hasConceptScore W2805565362C141071460 @default.
• W2805565362 hasConceptScore W2805565362C143998085 @default.
• W2805565362 hasConceptScore W2805565362C16005928 @default.
• W2805565362 hasConceptScore W2805565362C2776285725 @default.
• W2805565362 hasConceptScore W2805565362C2777673923 @default.

• next